Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Bruxism-related Symptomatology
NCT04722809Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in bruxism, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started May 2022; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
bruxism
Beyond the preview
Go deeper on NCT04722809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722809.